The therapy showed consistent efficacy and a manageable safety profile, with outcomes similar to those in the VISION trial. The findings support the use of PSMA-targeted radiopharmaceutical therapy in routine care for patients with mCRPC, including those eligible for retreatment.
Researchers evaluated PET imaging with radiolabeled trastuzumab deruxtecan and targeted alpha therapy against HER2-positive cancer cells, revealing promising results in tracking therapy accumulation and suppressing tumor growth. PET imaging also linked metabolic patterns to pancreatic tumor outcomes and identified potential distant met...
The new standard/guideline provides evidence-based recommendations for conducting and interpreting lung imaging, incorporating recent technological advances. It aims to promote comprehensive patient assessment and improve diagnostic accuracy, reproducibility, and patient outcomes.
Recent studies published in The Journal of Nuclear Medicine investigate novel radiohybrid ligands for prostate cancer therapy, AI models predicting prostate cancer survival, and PET tracers for meningioma treatment. These advancements show promise for personalized medicine and improved patient outcomes.
Early assessment with 68Ga-HER2 PET/CT during neoadjuvant therapy can predict pathologic complete response in patients with HER2-positive breast cancer, with a 85% success rate for those with tumor uptake decrease of at least 61%. This finding has implications for timely consideration of alternative treatment strategies or surgery.
Researchers developed new imaging approaches and tracers to target prostate cancer, breast cancer, and other conditions. These methods showed promising results in improving detection and treatment outcomes.
The Journal of Nuclear Medicine publishes a comprehensive supplement on theranostics, covering radionuclide production, personalized dosimetry, and phase 3 trials. Academic nuclear medicine must keep pace with industry funding and evidence-based practices to train specialists and meet demand.
A new study finds that PSMA PET/CT-guided targeted biopsy can detect clinically significant prostate cancer in 37% of men, compared to 21% with systematic biopsy alone. Combining the two approaches increases the detection rate to 41%.
Recent studies in The Journal of Nuclear Medicine have introduced new imaging techniques, including PET-based methods, to improve cancer diagnosis and treatment. Additionally, an open-source pipeline has been developed to automate tumor segmentation, and a new imaging approach has been shown to visualize therapeutic radionuclides.
Recent studies published in The Journal of Nuclear Medicine have investigated new treatments for liver fibrosis, thyroid cancer, and prostate cancer, including the use of PET tracers and radioactive iodine therapy. These studies have shown promising results, including improved imaging and biochemical responses, and increased radiation ...
A new radiotracer, 18F-FDG PET/CT, has been shown to be highly effective in detecting rare and aggressive kidney cancer, renal medullary carcinoma (RMC). The tracer identified lesions in 98% of RMC patients and led to a change in treatment plan for 21% of patients with active disease, highlighting its potential to improve patient care.
New research in nuclear medicine advances detection and treatment of clear cell renal cell carcinoma with high accuracy, while SSTR antagonists show potential for imaging and treatment of neuroendocrine tumors. Alternative beta-emitting radionuclides are also being explored for targeted radiopharmaceutical therapy.
Several new nuclear medicine approaches are being developed and evaluated for their potential to improve cancer imaging and treatment. Researchers have made significant progress in targeting specific markers and molecules in cancer cells, including CD163, CEACAM5, and DLL3. These advancements offer promising avenues for developing more...
A new study found that combining PET/MRI findings with EEG results and a structured presurgical evaluation improved the identification of seizure-causing brain tissue in pediatric epilepsy patients. 76 percent of patients who underwent surgery were free from seizures after two years of follow-up.
A new PET/MRI technique targeting fibroblast activation protein (FAP) overexpressed in endometriosis accurately maps the extent of the disease, enabling personalized management and improving patient outcomes. The approach was particularly effective in regions of the pelvis and abdomen that are typically difficult to image.
A new theranostic pair, 68Ga/177Lu-NYM096, shows excellent tumor uptake in clear cell renal cell carcinoma lesions and demonstrates early evidence of tumor response in patients. The radiotracer can identify tumors and deliver targeted radiotherapy, mitigating toxicity issues common with treatment.
Researchers developed a dual-threshold approach for measuring tumor volume on PET/CT, showing higher total lesion volume associated with shorter overall survival and time to treatment failure. FAPI PET/CT improved detection of ovarian cancer spread, while CD8-targeted PET tracked immune response in lung cancer.
PSMA PET/CT detected recurrent prostate cancer after minimally invasive treatments and identified malignant peripheral nerve sheath tumors with high accuracy. Researchers also found varying access to PSMA-targeted theranostics between Brazil and Europe.
Research published in The Journal of Nuclear Medicine highlights the importance of intermediate amyloid PET uptake in Alzheimer's disease diagnosis and its association with cognitive decline. Additionally, studies show promising results for early SPECT/CT response prediction in PSMA-positive prostate cancer treatment, as well as potent...
New research articles published in The Journal of Nuclear Medicine explore intensified PSMA-targeted therapy for advanced prostate cancer, as well as novel approaches to targeted radiopharmaceutical therapy. Studies also investigate radiation doses from PSMA-targeted therapy and their relationship with treatment outcomes, while others ...
A new study published in The Journal of Nuclear Medicine has found that dual-energy SPECT may enable faster monitoring of PSMA therapy, reducing imaging time from 18 minutes to 9 minutes. Another study showed a prognostic model using PSMA PET can predict outcomes after therapy, including overall survival and PSA progression-free survival.
Researchers found that high brain metabolism is associated with longer overall survival, and it's an independent prognostic factor for overall survival. Brain metabolism measured by ¹⁸F-FDG PET/CT provides valuable insight into patient outcomes and may help identify patients most likely to benefit from early supportive care.
A new study found that PET/CT scans improved the diagnosis of fever of unknown origin (FUO) in nearly 75% of patients. The study identified predictive markers for a positive scan, including high C-reactive protein and short duration of prior antibiotic therapy.
A noninvasive DNA blood test can identify patients with metastatic castration-resistant prostate cancer most likely to benefit from <sup> 223 </sup> Ra radiopharmaceutical therapy and monitor their progress. The test showed associations between ctDNA profiles and clinical outcomes, including biomarker response and overall survival.
Researchers have made significant breakthroughs in targeted radiation therapy for pancreatic cancer, PARP inhibitor treatment, and Alzheimer's disease detection. New PET-based scores may predict prostate cancer outcomes, while blood cell mutations are associated with side effects in advanced prostate cancer patients.
Recent studies published in The Journal of Nuclear Medicine have shown that combining multiparametric MRI with PET improves the detection of clinically significant prostate cancer. Additionally, PSMA PET/CT-guided biopsies have been found to detect more significant cancers than standard biopsies.
A second PSMA PET scan changed treatment plans for nearly half of patients whose first scan was negative, detecting evidence of disease in 56% of cases. The study found that repeat imaging was most likely to detect disease in patients with higher PSA levels and a PSA doubling time of less than twelve months.
The Journal of Nuclear Medicine (JNM) has increased its impact factor from 9.1 to 9.6, ranking eighth overall among medical imaging journals. The journal saw a nearly 10% increase in citations and improved performance in various categories.
Researchers evaluated two somatostatin receptor PET tracers for breast cancer treatment, found SSTR-positive tumors in many estrogen receptor-positive cases. A new PET tracer showed promise for detecting Staph infections, while an interim PET scan may help track response to PSMA therapy in advanced prostate cancer.
Mary Beth Farrell has been honored with the 2026 SNMMI-TS Lifetime Achievement Award for her decades-long dedication to elevating the nuclear medicine profession. Her leadership in accreditation, research, and education has shaped national standards and driven quality improvement initiatives that continue to impact patient care.
A novel FAP-targeted radiopharmaceutical therapy approach has shown safety and effectiveness in treating various types of cancer, including breast, colorectal, gastric, and ovarian cancers. The treatment achieved objective responses in approximately two-thirds of patients and disease control in over 80%.
Research on targeted radioactive gold nanoparticles shows promise against aggressive brain tumors. Ultra-high-resolution PET scanners provide detailed views of mouse brains. New imaging tracers target key drivers of prostate cancer growth.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has announced the recipients of five Drs. Jane & Abass Alavi Mars Shot Research Awards, supporting studies on inflammatory bowel disease, artery inflammation, and other conditions.
The Journal of Nuclear Medicine has published several groundbreaking studies on targeted radiotherapy approaches for various types of cancer. Researchers have successfully identified tumors using fibroblast activation protein (FAP)-targeting compounds and explored the potential of PET/MRI scans in detecting endometriosis and recurrent ...
The SNMMI 2026 Annual Meeting showcased significant advancements in precision nuclear medicine, AI, theranostics, and molecular imaging. The meeting featured over 1,500 abstracts, a 25% increase from last year's meeting, and presented new educational sessions alongside networking opportunities.
Heather Jacene, MD, has been named president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), with a focus on strengthening the organization and advancing nuclear medicine. She plans to create new opportunities for members to participate actively in SNMMI and conduct multidisciplinary collaborations.
Jason Lewis, PhD, FSNMMI, has been elected as SNMMI's vice president-elect. He aims to strengthen education, scientific exchange, and outreach efforts to integrate basic scientists into SNMMI programs. Lewis holds various academic and research positions.
Gary Ulaner, a renowned nuclear medicine expert, has been elected president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). He aims to advance SNMMI's Mars Shot initiative, expand educational activities for professionals, and increase funding for training new radiochemistry and physics specialists.
A new PET imaging approach measures synaptic density in the spinal cord, allowing physicians to monitor disease progression and evaluate treatment effectiveness. This technique detects widespread reductions in synaptic connections across the brain and spinal cord in patients with multiple sclerosis.
A new end-to-end PET imaging approach for osteosarcoma distinguishes tumor tissue from normal tissue and assesses surgical margins in real-time. The platform enables precise tumor resection, reducing the risk of local recurrence and preserving maximum limb function.
Researchers have identified RET as a biomarker for neuroendocrine prostate cancer and developed a theranostic pair for PET imaging and radioligand therapy. The approach demonstrates high uptake in tumors and shows promise for treatment, offering an alternative to current PSMA-based imaging.
A newly developed portable point-of-care PET technology provides high-quality results for guiding biopsies, tumor ablations, and other interventional procedures. The bedside device offers real-time visual feedback, making it a cost-effective approach for hospitals to perform procedures in constrained clinical environments.
A new PET tracer targeting carbonic anhydrase IX (CAIX) has demonstrated exceptional sensitivity and high tumor-to-background contrast in detecting clear cell renal cell carcinoma (ccRCC). The tracer successfully identified additional metastatic lesions missed by standard imaging while reducing abdominal background noise.
A novel PET imaging framework reveals bariatric surgery induces coordinated changes in metabolic function across organs, including fat, liver, pancreas, muscle, and immune-endocrine organs. These findings support the use of whole-body PET/CT as a tool to map organ-level metabolic health.
A new PET radiotracer can effectively image overactive adrenal glands, allowing for a non-invasive approach to diagnose primary aldosteronism. This could enable physicians to tailor treatment plans for patients with this condition.
Dr. Martin G. Pomper has been awarded the 2026 Benedict Cassen Prize for his outstanding contributions to nuclear medicine, particularly in the development of PSMA-targeted agents. His work has led to significant advances in cancer diagnosis and treatment, including the creation of commercial PSMA-targeted PET agents.
A new PET radiotracer, 18F-GP1 PET/CT, accurately detects deep vein thrombosis in the legs and reveals lung clot migration. The approach may support faster diagnosis and improve patient care by detecting disease early.
A study found that a specific pattern of brain metabolism visualized with PET imaging can predict which patients are most likely to benefit from Alzheimer's disease therapy. Patients with this pattern experienced stabilized cognitive performance, while those with other patterns had significant cognitive decline.
Researchers developed a new tau PET radiotracer that can accurately detect chronic traumatic encephalopathy (CTE) in living patients. The tracer's ability to bind to tau pathology was confirmed in post-mortem CTE tissue, and preliminary results suggest it could provide an early diagnostic biomarker for the disease.
A new type of peptide receptor radionuclide therapy (PRRT) shows promise in treating metastatic neuroendocrine tumors. The novel approach resulted in partial remission in the majority of patients with advanced cases, with manageable safety and encouraging antitumor activity.